View in EDS HTML Full Text PDF Full Text

Comparative analysis of dimethyl fumarate and teriflunomide in relapsing–remitting multiple sclerosis.

Saved in:
Bibliographic Details
Title: Comparative analysis of dimethyl fumarate and teriflunomide in relapsing–remitting multiple sclerosis.
Authors: Müller, Jannis (AUTHOR), Schädelin, Sabine (AUTHOR), Lorscheider, Johannes (AUTHOR), Benkert, Pascal (AUTHOR), Hänni, Peter (AUTHOR), Schmid, Jürg (AUTHOR), Kuhle, Jens (AUTHOR), Derfuss, Tobias (AUTHOR), Granziera, Cristina (AUTHOR), Yaldizli, Özgür (AUTHOR)
Source: European Journal of Neurology. Dec2023, Vol. 30 Issue 12, p3809-3818. 10p.
Subjects: Dimethyl fumarate, Multiple sclerosis, Proportional hazards models, Disease relapse, Comparative studies
Abstract: Background and purpose: In relapsing–remitting multiple sclerosis (RRMS), analyses from observational studies comparing dimethyl fumarate (DMF) and teriflunomide showed conflicting results. We aimed to compare the effectiveness of DMF and teriflunomide in a real‐world setting, where both drugs are licensed as first‐line therapies for RRMS. Methods: We included all patients who initiated DMF or teriflunomide between 2013 and 2022, listed in the Swiss National Treatment Registry. Coarsened exact matching was applied using age, gender, disease duration, baseline Expanded Disability Status Scale (EDSS) score, time since last relapse, and relapse rate in the previous year as matching variables. Time to relapse and time to 12‐month confirmed EDSS worsening were compared using Cox proportional hazard models. Results: In total, 2028 patients were included in this study, of whom 1498 were matched (DMF: n = 1090, 69.6% female, mean age 45.1 years, median EDSS score 2.0; teriflunomide: n = 408, 68.9% female, mean age 45.1 years, median EDSS score 2.0). Time to relapse and time to EDSS worsening was longer in the DMF than the teriflunomide group (hazard ratio 0.734, p = 0.026 and hazard ratio 0.576, p = 0.003, respectively). Conclusion: Analysis of real‐world data showed that DMF treatment was associated with more favorable outcomes than teriflunomide treatment. [ABSTRACT FROM AUTHOR]
Copyright of European Journal of Neurology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 173516195
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Comparative analysis of dimethyl fumarate and teriflunomide in relapsing–remitting multiple sclerosis.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Müller%2C+Jannis%22">Müller, Jannis</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Schädelin%2C+Sabine%22">Schädelin, Sabine</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Lorscheider%2C+Johannes%22">Lorscheider, Johannes</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Benkert%2C+Pascal%22">Benkert, Pascal</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Hänni%2C+Peter%22">Hänni, Peter</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Schmid%2C+Jürg%22">Schmid, Jürg</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Kuhle%2C+Jens%22">Kuhle, Jens</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Derfuss%2C+Tobias%22">Derfuss, Tobias</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Granziera%2C+Cristina%22">Granziera, Cristina</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Yaldizli%2C+Özgür%22">Yaldizli, Özgür</searchLink> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22European+Journal+of+Neurology%22">European Journal of Neurology</searchLink>. Dec2023, Vol. 30 Issue 12, p3809-3818. 10p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Dimethyl+fumarate%22">Dimethyl fumarate</searchLink><br /><searchLink fieldCode="DE" term="%22Multiple+sclerosis%22">Multiple sclerosis</searchLink><br /><searchLink fieldCode="DE" term="%22Proportional+hazards+models%22">Proportional hazards models</searchLink><br /><searchLink fieldCode="DE" term="%22Disease+relapse%22">Disease relapse</searchLink><br /><searchLink fieldCode="DE" term="%22Comparative+studies%22">Comparative studies</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: Background and purpose: In relapsing–remitting multiple sclerosis (RRMS), analyses from observational studies comparing dimethyl fumarate (DMF) and teriflunomide showed conflicting results. We aimed to compare the effectiveness of DMF and teriflunomide in a real‐world setting, where both drugs are licensed as first‐line therapies for RRMS. Methods: We included all patients who initiated DMF or teriflunomide between 2013 and 2022, listed in the Swiss National Treatment Registry. Coarsened exact matching was applied using age, gender, disease duration, baseline Expanded Disability Status Scale (EDSS) score, time since last relapse, and relapse rate in the previous year as matching variables. Time to relapse and time to 12‐month confirmed EDSS worsening were compared using Cox proportional hazard models. Results: In total, 2028 patients were included in this study, of whom 1498 were matched (DMF: n = 1090, 69.6% female, mean age 45.1 years, median EDSS score 2.0; teriflunomide: n = 408, 68.9% female, mean age 45.1 years, median EDSS score 2.0). Time to relapse and time to EDSS worsening was longer in the DMF than the teriflunomide group (hazard ratio 0.734, p = 0.026 and hazard ratio 0.576, p = 0.003, respectively). Conclusion: Analysis of real‐world data showed that DMF treatment was associated with more favorable outcomes than teriflunomide treatment. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of European Journal of Neurology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=173516195
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1111/ene.16044
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 10
        StartPage: 3809
    Subjects:
      – SubjectFull: Dimethyl fumarate
        Type: general
      – SubjectFull: Multiple sclerosis
        Type: general
      – SubjectFull: Proportional hazards models
        Type: general
      – SubjectFull: Disease relapse
        Type: general
      – SubjectFull: Comparative studies
        Type: general
    Titles:
      – TitleFull: Comparative analysis of dimethyl fumarate and teriflunomide in relapsing–remitting multiple sclerosis.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Müller, Jannis
      – PersonEntity:
          Name:
            NameFull: Schädelin, Sabine
      – PersonEntity:
          Name:
            NameFull: Lorscheider, Johannes
      – PersonEntity:
          Name:
            NameFull: Benkert, Pascal
      – PersonEntity:
          Name:
            NameFull: Hänni, Peter
      – PersonEntity:
          Name:
            NameFull: Schmid, Jürg
      – PersonEntity:
          Name:
            NameFull: Kuhle, Jens
      – PersonEntity:
          Name:
            NameFull: Derfuss, Tobias
      – PersonEntity:
          Name:
            NameFull: Granziera, Cristina
      – PersonEntity:
          Name:
            NameFull: Yaldizli, Özgür
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 12
              Text: Dec2023
              Type: published
              Y: 2023
          Identifiers:
            – Type: issn-print
              Value: 13515101
          Numbering:
            – Type: volume
              Value: 30
            – Type: issue
              Value: 12
          Titles:
            – TitleFull: European Journal of Neurology
              Type: main
ResultId 1